ALNYLAM PHARMACEUTICALS, INC. stock analysis
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute he
- Ticker
- ALNY
- Exchange
- Nasdaq
- Sector
- Health Care
- Industry
- Pharmaceuticals
What should I review before buying ALNYLAM PHARMACEUTICALS, INC. stock?
Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.
Inside the full analysis
- Valuation
- Growth
- Financial health
- Ownership
- Research
Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.
Sign in to open the analysis